{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T10:48:22Z","timestamp":1787914102431,"version":"build-2784847793"},"reference-count":48,"publisher":"Elsevier BV","issue":"27","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,13]],"date-time":"2022-05-13T00:00:00Z","timestamp":1652400000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.vaccine.2022.05.025","type":"journal-article","created":{"date-parts":[[2022,5,20]],"date-time":"2022-05-20T08:29:13Z","timestamp":1653035353000},"page":"3802-3811","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["The cost-effectiveness of human papillomavirus vaccination in the Philippines"],"prefix":"10.1016","volume":"40","author":[{"given":"Cecilia L.","family":"Llave","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Esterlita V.","family":"Uy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilton Y.","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josephine G.","family":"Aldaba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clarence C.","family":"Yacapin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle B.","family":"Miranda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haidee A.","family":"Valverde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilda T.","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saira","family":"Nawaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rose C.","family":"Slavkovsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Mooney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7370-0919","authenticated-orcid":false,"given":"Elisabeth L.","family":"Vodicka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2022.05.025_b0005","unstructured":"IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Human Papillomaviruses. Lyon (FR): International Agency for Research on Cancer; 2007. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, No. 90. 1, Human Papillomavirus (HPV) Infection. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK321770\/."},{"key":"10.1016\/j.vaccine.2022.05.025_b0010","unstructured":"World Health Organization International Agency for Research on Cancer (IARC).Global Cancer Observatory, https:\/\/gco.iarc.fr\/; 2020. [accessed 13 April 2021]."},{"issue":"4","key":"10.1016\/j.vaccine.2022.05.025_b0015","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/ijc.30716","article-title":"Worldwide burden of cancer attributable to HPV by site, country and HPV type","volume":"141","author":"de Martel","year":"2017","journal-title":"Int J Cancer"},{"key":"10.1016\/j.vaccine.2022.05.025_b0020","unstructured":"Bruni L, Albero G, Serrano B et al. ICO\/IARC Information Centre on HPV and Cancer (HPV Information Centre). Human Papillomavirus and Related Diseases in Philippines. Summary Report, https:\/\/www.hpvcentre.net\/statistics\/reports\/PHL_FS.pdf?t=1593852267479; 17 June 2019 [accessed 03 July 2020]."},{"key":"10.1016\/j.vaccine.2022.05.025_b0025","article-title":"Efficacy of human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomized study in young women","volume":"374:301\u201314; PMID:19586656","author":"Paavonen","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2022.05.025_b0030","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1056\/NEJMoa061741","article-title":"Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions","volume":"356","author":"The FUTURE II Study Group","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2022.05.025_b0035","doi-asserted-by":"crossref","unstructured":"Bergman H, Buckley BS, Villanueva G, Petkovic J, Garritty C, Lutje V, et al. Comparison of different human papillomavirus (HPV) vaccine types and dose schedules for prevention of HPV\u2010related disease in females and males. Cochrane Database of Systematic Reviews 2019;11:CD013479. doi: https:\/\/doi.org\/10.1002\/14651858.CD013479.","DOI":"10.1002\/14651858.CD013479"},{"key":"10.1016\/j.vaccine.2022.05.025_b0040","unstructured":"National Cancer Institute. Human papillomavirus (HPV) vaccines, https:\/\/www.cancer.gov\/about-cancer\/causes-prevention\/risk\/infectious-agents\/hpv-vaccine-fact-sheet [accessed 15 April 2021]."},{"key":"10.1016\/j.vaccine.2022.05.025_b0045","unstructured":"HPV vaccine manufacturers commit to provide enough supply to immunise at least 84 million girls in Gavi countries, http:\/\/www.innovax.cn\/en\/news_view.aspx?newsCateid=56&cateid=56&NewsId=996; 19 July 2020 [accessed 28 March 2021]."},{"key":"10.1016\/j.vaccine.2022.05.025_b0050","unstructured":"PATH. New HPV vaccine from Innovax receives WHO prequalification, https:\/\/www.path.org\/media-center\/new-hpv-vaccine-innovax-receives-who-prequalification\/;19 October 2021 [accessed 06 January 2022]."},{"key":"10.1016\/j.vaccine.2022.05.025_b0055","doi-asserted-by":"crossref","unstructured":"Wheeler CM, Castellsague X, Garland SM, Szarewski A, Paavonen J, Naud P, et al. Cross-protective efficacy of HPV-16\/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012;13(1):100-10. doi: https:\/\/doi.org\/10.1016\/S1470-2045(11)70287-X.","DOI":"10.1016\/S1470-2045(11)70287-X"},{"key":"10.1016\/j.vaccine.2022.05.025_b0060","doi-asserted-by":"crossref","unstructured":"Brown DR, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, et al. The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus-like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Generally HPV-Naive Women Aged 16-26 Years. J Infect Dis 2009;199(7):926-35. doi: https:\/\/doi.org\/10.1086\/597307.","DOI":"10.1086\/597307"},{"issue":"10108","key":"10.1016\/j.vaccine.2022.05.025_b0065","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1016\/S0140-6736(17)31821-4","article-title":"Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16\u201326 years: a randomised, double-blind trial","volume":"390","author":"Huh","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2022.05.025_b0070","doi-asserted-by":"crossref","unstructured":"Qiao YL, Wu T, Li RC, HU YM, Wie LH, Li CG, et al. Efficacy, Safety, and Immunogenicity of an Escherichia coli-Produced Bivalent Human Papillomavirus Vaccine: An Interim Analysis of a Randomized Clinical Trial. J Natl Cancer Inst 2020;112(2):145-53. doi: https:\/\/doi.org\/10.1093\/jnci\/djz074.","DOI":"10.1093\/jnci\/djz074"},{"key":"10.1016\/j.vaccine.2022.05.025_b0075","unstructured":"World Health Organization. Human Papillomavirus Vaccines: WHO Position Paper, May 2017\u2013Recommendations, https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/255353\/WER9219.pdf;jsessionid=C43AA119C5F5CDD034F7BAAB66B34A7C?sequence=1; May 2017 [accessed 03 July 2020]."},{"issue":"11","key":"10.1016\/j.vaccine.2022.05.025_b0080","doi-asserted-by":"crossref","first-page":"821","DOI":"10.2471\/BLT.11.089862","article-title":"Human papillomavirus vaccine delivery strategies that achieved high coverage in low- and middle-income countries","volume":"89","author":"LaMontagne","year":"2011","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.vaccine.2022.05.025_b0085","unstructured":"Department of Health (DOH). Department memorandum no. 2013-0291: Guidelines in the implementation of human papillomavirus (HPV) vaccination in selected schools, https:\/\/doh.gov.ph\/sites\/default\/files\/publications\/DOHGuidelinesSchoolbasedHPVvaccination.pdf; August 2013 [accessed 16 April 2021]."},{"key":"10.1016\/j.vaccine.2022.05.025_b0090","unstructured":"Department of Health (DOH). Department memorandum no. 2015-0316: Guidelines in the implementation of human papillomavirus (HPV) vaccination, https:\/\/doh.gov.ph\/sites\/default\/files\/health_programs\/DM%202015-0316%20Guidelines%20in%20the%20Implementation%20of%20HPV%20Vaccination_0.pdf; August 2015 [accessed 16 April 2021]."},{"issue":"2","key":"10.1016\/j.vaccine.2022.05.025_b0095","doi-asserted-by":"crossref","DOI":"10.7189\/jogh.08.020312","article-title":"Dengvaxia controversy: impact on vaccine hesitancy","volume":"8","author":"Fatima","year":"2018","journal-title":"J Glob Health"},{"issue":"5","key":"10.1016\/j.vaccine.2022.05.025_b0100","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1080\/21645515.2016.1269991","article-title":"Cost-Effectiveness Analysis of AS04-Adjuvanted Human Papillomavirus 16\/18 Vaccine Compared with Human Papillomavirus 6\/11\/16\/18 Vaccine in the Philippines, with the New 2-Dose Schedule","volume":"13","author":"Germar","year":"2017","journal-title":"Human Vaccines Immunotherapeutics"},{"issue":"1","key":"10.1016\/j.vaccine.2022.05.025_b0105","doi-asserted-by":"crossref","DOI":"10.1186\/s12889-015-2046-1","article-title":"A Cost-Utility Analysis of Cervical Cancer Screening and Human Papillomavirus Vaccination in the Philippines","volume":"15","author":"Guerrero","year":"2015","journal-title":"BMC Public Health"},{"key":"10.1016\/j.vaccine.2022.05.025_b0110","unstructured":"Domingo E, Alzona M, Pelaez-Crisologo C, Pavelyev A, LeVan R, Prabhu VS. Cost-effectiveness and public-health impact of a nonavalent HPV vaccine compared with a bivalent or quadrivalent HPV vaccine in Philippines using a transmission dynamic model (Abstract). Presented at the International Papillomavirus Conference. Sydney, Australia. https:\/\/ipvconference.org\/wp-content\/uploads\/sites\/40\/2019\/01\/IPVC-2018-Abstracts.pdf ; 02-06 October 2018 [accessed 04 July 2020]."},{"key":"10.1016\/j.vaccine.2022.05.025_b0115","unstructured":"Pan American Health Organization. PROVAC Toolkit, https:\/\/www.paho.org\/provac-toolkit\/tools\/about-univac\/ [accessed 28 March 2021]."},{"issue":"6","key":"10.1016\/j.vaccine.2022.05.025_b0120","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/j.vaccine.2019.12.013","article-title":"Potential Health Impact and Cost-Effectiveness of Bivalent Human Papillomavirus (HPV) Vaccination in Afghanistan","volume":"38","author":"Anwari","year":"2020","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2022.05.025_b0125","doi-asserted-by":"crossref","first-page":"e0228506","DOI":"10.1371\/journal.pone.0228506","article-title":"Introduction of rotavirus vaccination in Palestine: An evaluation of the costs, impact and cost-effectiveness of Rotarix and Rotavac","volume":"15","author":"Debellut","year":"2020","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2022.05.025_b0130","doi-asserted-by":"crossref","first-page":"C19","DOI":"10.1016\/j.vaccine.2013.05.045","article-title":"TRIVAC decision support model for evaluating the cost-effectiveness of Haemophilus influenza type b, pneumococcal and rotavirus vaccination","volume":"31","author":"Clark","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.05.025_b0135","unstructured":"Health Technology Assessment Unit, Department of Health - Philippines. Philippine HTA Methods Guide, https:\/\/hta.doh.gov.ph\/philippine-hta-methods-guide\/; 2020 [accessed 28 March 2021]."},{"issue":"1","key":"10.1016\/j.vaccine.2022.05.025_b0140","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s40273-016-0451-7","article-title":"Challenges in Cost-Effectiveness Analysis Modelling of HPV Vaccines in Low- and Middle-Income Countries: A Systematic Review and Practice Recommendations","volume":"35","author":"Ekwunife","year":"2017","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.vaccine.2022.05.025_b0145","unstructured":"Daily Philippine Peso per U.S. Dollar Rate. Banko Sentral ng Pilipinas, https:\/\/www.bsp.gov.ph\/statistics\/external\/day99.aspx [accessed 13 April 2021]."},{"issue":"1","key":"10.1016\/j.vaccine.2022.05.025_b0150","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/ijgo.12749","article-title":"Revised FIGO staging for carcinoma of the cervix uteri","volume":"145","author":"Bhatla","year":"2019","journal-title":"Int J Gynecol Obstet"},{"key":"10.1016\/j.vaccine.2022.05.025_b0155","unstructured":"Philippine General Hospital, Department of Obstetrics and Gynecology, Division of Gynecologic Oncology. 2019 Annual Report. 2019."},{"key":"10.1016\/j.vaccine.2022.05.025_b0160","unstructured":"Global Burden of Disease Collaborative Network. Global Burden of Disease Study 2017 (GBD 2017) Disability Weights. Seattle, United States: Institute for Health Metrics and Evaluation (IHME), http:\/\/ghdx.healthdata.org\/sites\/default\/files\/record-attached-files\/IHME_GBD_2017_DISABILITY_WEIGHTS_INFO_SHEET_Y2018M11D08.PDF; 2018 [accessed 28 March 2021]."},{"key":"10.1016\/j.vaccine.2022.05.025_b0165","unstructured":"Philippine Health Insurance Corporation. PhilHealth Circular No. 0031 series 2013, https:\/\/www.philhealth.gov.ph\/circulars\/2013\/circ31_2013.pdf; 2013 [accessed 13 April 2021]."},{"key":"10.1016\/j.vaccine.2022.05.025_b0170","unstructured":"National Wages and Productivity Commission, https:\/\/nwpc.dole.gov.ph\/ [accessed 13 April 2021]."},{"key":"10.1016\/j.vaccine.2022.05.025_b0175","unstructured":"World Health Organization. MI4A: Market Information for Access to Vaccines, https:\/\/www.who.int\/immunization\/programmes_systems\/procurement\/mi4a\/platform\/en\/; August 2019 [accessed 13 April 2021]."},{"key":"10.1016\/j.vaccine.2022.05.025_b0180","series-title":"Version 1 Preprint Available November 19","article-title":"Efficacy of single-dose HPV vaccination among young African women","author":"Barnabas","year":"2021"},{"key":"10.1016\/j.vaccine.2022.05.025_b0185","unstructured":"Immunization Economics. Org. Immunization Delivery Cost Catalogue, http:\/\/immunizationeconomics.org\/ican-idcc [accessed 13 April 2021]."},{"key":"10.1016\/j.vaccine.2022.05.025_b0190","unstructured":"Gavi-supported HPV vaccine profiles to support country decision-making. HPV Working Group \u2013 Gavi Secretariat and partners, https:\/\/www.gavi.org\/sites\/default\/files\/2020-09\/Gavi-HPV-vaccines-September-2020-1.pdf; September 2020 [accessed 13 April 2021]."},{"key":"10.1016\/j.vaccine.2022.05.025_b0195","unstructured":"The World Bank. GDP per capita, https:\/\/data.worldbank.org\/indicator\/NY.GDP.PCAP.CD [accessed 03 April 2021]."},{"issue":"37","key":"10.1016\/j.vaccine.2022.05.025_b0200","doi-asserted-by":"crossref","first-page":"3786","DOI":"10.1016\/j.vaccine.2013.06.060","article-title":"Cost-effectiveness of human papillomavirus vaccination in low and middle income countries: A systematic review","volume":"31","author":"Fesenfeld","year":"2013","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2022.05.025_b0205","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1080\/14760584.2018.1411195","article-title":"Cost effectiveness of human papilloma virus vaccination in low and middle income countries: a systematic review of literature","volume":"17","author":"Silas","year":"2018","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2022.05.025_b0210","unstructured":"Philippine government. Executive Order no. 49, series of 1993: Directing the mandatory use of the Philippines National Drug Formulary (PNDF) as the basis for the procurement of drug products by the government, https:\/\/www.officialgazette.gov.ph\/1993\/01\/21\/executive-order-no-49-s-1993\/ [accessed 10 April 2021]."},{"key":"10.1016\/j.vaccine.2022.05.025_b0215","first-page":"1","article-title":"Health Devolution in the Philippines: Lessons and Insights","author":"Cuenca","year":"2018","journal-title":"Philipp Inst Dev Stud"},{"key":"10.1016\/j.vaccine.2022.05.025_b0220","doi-asserted-by":"crossref","first-page":"e406","DOI":"10.1016\/S2214-109X(14)70237-2","article-title":"Cost-effectiveness of female human papillomavirus vaccination in 179 countries: a PRIME modelling study","volume":"2","author":"Jit","year":"2014","journal-title":"Lancet Glob Heal"},{"key":"10.1016\/j.vaccine.2022.05.025_b0225","unstructured":"PhilHealth. Stats and Charts, https:\/\/www.philhealth.gov.ph\/about_us\/statsncharts\/snc2020_1stSem.pdf; 2020 [accessed 03 April 2021]."},{"key":"10.1016\/j.vaccine.2022.05.025_b0230","unstructured":"Philippine Statistics Authority. Philippine National Health Accounts: 2014-2019, https:\/\/psa.gov.ph\/sites\/default\/files\/Publication%20PNHA%202019%20signed_1.pdf; October 2020 [accessed 03 April 2021]."},{"issue":"2","key":"10.1016\/j.vaccine.2022.05.025_b0235","doi-asserted-by":"crossref","first-page":"125","DOI":"10.47895\/amp.v52i2.418","article-title":"Philippine costs in oncology (PESO): Describing the economic impact of cancer on Filipino cancer patients using the ASEAN costs in oncology study dataset","volume":"52","author":"Ngelangel","year":"2018","journal-title":"Acta Med Philipp"},{"key":"10.1016\/j.vaccine.2022.05.025_b0240","unstructured":"Department of Health- Health Policy Development and Planning Bureau. DOH- Budget Briefer 2021, https:\/\/doh.gov.ph\/sites\/default\/files\/publications\/2021-Budget-Briefer.pdf; 2021 [accessed 07 April 2021]."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22006090?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22006090?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:13:42Z","timestamp":1759403622000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X22006090"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":48,"journal-issue":{"issue":"27","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S0264410X22006090"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.05.025","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The cost-effectiveness of human papillomavirus vaccination in the Philippines","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.05.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}